Merck | MRK - Cash And Equivalent


Merck reported EUR2.33B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Adidas EUR 873M 744M Mar/2026
Adyen EUR 10.42B 1.99B Dec/2025
Akzo Nobel EUR 1.62B 66M Dec/2025
Alcon AG USD 1.58B 80M Mar/2026
Amadeus IT EUR 975.6M 7.4M Dec/2025
Amarin USD 131.06M 3.6M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BASF EUR 2.67B 811M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Beiersdorf EUR 1.2B 33M Dec/2025
Covestro EUR 648M 44M Dec/2025
Danone EUR 1.98B 364M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Genmab DKK 1.72B 46M Dec/2025
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 801M 242.31M Dec/2025
Henkel EUR 2.71B 163M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Infineon EUR 1.3B 64M Mar/2026
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Linde USD 3.96B 1.1B Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Philips EUR 2.79B 882M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
UCB EUR 1.57B 1.14B Dec/2024